Online inquiry

IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3421MR)

This product GTTS-WQ3421MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets HGF gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000601.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3082
UniProt ID P14210
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3421MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ926MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-321
GTTS-WQ14993MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ1547MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACE-041
GTTS-WQ13787MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-10933
GTTS-WQ3069MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ11945MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ11408MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI-575
GTTS-WQ2323MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ALXN6000
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW